All In Biotech

Drug Trial Radar · NCT02760407

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,648 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,648

Actual

Start

Jun 6, 2016

Primary completion

Aug 2, 2019

Study completion Nov 5, 2019

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
Quintiles, Inc.; OCT Clinical Trials
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of OKZ 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active RA inadequately controlled by MTX therapy. The secondary objective was to evaluate the efficacy of OKZ relative to adalimumab in subjects with moderately to severely active RA inadequately controlled by MTX therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Olokizumab 64mg q4wDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • Olokizumab 64mg q2wDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • Adalimumab 40mg q2wDrug

    0.4 or 0.8 mL prefilled, single-dose syringe

  • Placebo q2wDrug

    sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) ResponseTime frame: at Week 12

Locations

203 sites in 18 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Sun City, Arizona

  • Medvin Clinical Research

    Covina, California

  • TriWest Research Associates

    El Cajon, California

  • MD Med Corp.

    Hemet, California

  • Valerius Medical Group

    Los Alamitos, California

  • Rheumatology Center of San Diego

    San Diego, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Pacific Arthritis Center Medical Grpoup

    Santa Maria, California

  • Inland Rheumatology Clinical Trials

    Upland, California

  • Center for Rheumatology Research

    West Hills, California

  • Medvin Clinical Research

    Whittier, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • New England Research Associates LLC

    Bridgeport, Connecticut

  • Javed Rheumatology Associates

    Newark, Delaware

  • RASF - Clinical Research Center

    Boca Raton, Florida

  • Reliable Clinical Research, LLC

    Hialeah, Florida

  • Pharmax Research Clinic, Inc.

    Miami, Florida

  • Medical Research Center of Miami

    Miami, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Arthritis Research

    Palm Harbor, Florida

  • Family Clinical Trials, LLC.

    Pembroke Pines, Florida

  • AdventHealth Medical Group, PA

    Tampa, Florida

  • Lovelace Scientific Resources, Inc.

    Venice, Florida

  • Arthritis Center of North Georgia

    Gainesville, Georgia

  • Marietta Rheumatology Associates, PC

    Marietta, Georgia

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • Springfield Clinic, LLP

    Springfield, Illinois

  • University of Kansas Hospital

    Kansas City, Kansas

  • Graves Gilbert Clinic

    Bowling Green, Kentucky

  • The Arthritis & Diabetes Clinic, Inc.

    Monroe, Louisiana

  • Klein and Associates, M.D., P.A.

    Hagerstown, Maryland

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • North MS Medical Clinics, Inc.

    Tupelo, Mississippi

  • Glacier View Research Instutute-Rheumatology

    Kalispell, Montana

  • Physician Resrch Collaboration

    Lincoln, Nebraska

  • Arthritis & Osteoporosis Associates, PA

    Freehold, New Jersey

  • NYU Langone ambulatory care

    Brooklyn, New York

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.